Worldwide Reports

Use of Recombinant Factor VIIa in Obstetrics

Chuni N | British Journal of Medicine & Medical Research |
Melaka Manipal Medical College
Melaka, Malacca, Malaysia

en.labelReadArticle
Abstract

The objective of this review article was to evaluate the current literature on the increasing off-label use of rFVIIa in the management of critical obstetric haemorrhage. Given the lack of high-level evidence, there is a need to review the clinical indications, observed response and adverse events. This review is designed to aid practitioners in deciding when and how to administer rFVIIa; since the current evidence from observational studies shows that benefits outweigh risks in its use as an adjunct to conventional treatment in massive haemorrhage. However, pregnancy is a potentially thrombogenic state, hence a cautious approach is required in patients with risk factors for thromboembolic complications.

We offer free consulting services for administrators and physician leaders wishing to establish a bloodless medicine and surgery program.
Interested in starting a bloodless program?

Learn how you can implement a bloodless program in your institution.

Are you a patient?

Learn more about bloodless medicine and surgery.